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Sammendrag  
In vivo MR spektroskopi (MRS) er en teknikk hvor biokjemisk informasjon kan 
hentes ut fra et definert volum, ofte på størrelse med en sukkerbit.  Volumet velges ut 
anatomiske MR bildene tatt av pasienten på forhånd, og opptaket av et spekter gjøres i 
løpet av få minutter.  Denne avhandlingen som består av fire studier, er basert på 
ideen om at MRS kan være et tilleggsverktøy i den kliniske hverdagen.  I den første 
studien er MRS brukt i studie av ungdommer født med ekstra lav fødselsvekt i forhold 
til barn med normalvekt, mens i de tre siste studiene er det fokusert på kreftpasienter. 
Multivariat dataanalyse er benyttet for å klassifisere MR spektrene. 
 
Ekstra lav fødselsvekt har vist seg å innebære en risiko for senere utvikling av 
nevrologiske lidelser. Artikkel I oppsummerer en studie av ungdommer med 
forskjellig fødselsvekt undersøkt med MRI og in vivo MRS av venstre frontallapp i 
hvit hjernesubstans. For å avdekke forskjeller av betydning i fordeling av 
hjernemetabolittene er det brukt både forholdsberegninger (ratio) og multivariat 
dataanalyse til analyse av. Klassifiseringen av ungdommene ble basert på forskjellene 
i de metabolske mønstrene som bare ble observert i de multivariate analysene.  
Resultatene var i overensstemmelse med observasjonene gjort i tidligere studier av 
barna, med hensyn på motoriske egenskaper og psykiatriske symptom. 
 
Forskjellene i MR spekter av friskt og sykt vev er ofte så tydelige at man ved enkle 
metoder som for eksempel beregninger av metabolittforhold, kan klassifisere dem.  
Eksempler på slike spekter er vist i artikkel II, hvor både friske frivillige og pasienter 
med hjernemetastaser ble brukt til å vurdere effekten av økt magnetfeltstyrke.  I denne 
artikkelen var målet å finne ut i hvor stor grad signalintensiteten (SNR) og 
oppløsningen i spektrene fra 3T-systemet ble forbedret i forhold til det som ble 
oppnådd ved 1.5T-systemet.  Resultatene basert på beregning av metabolittforhold, 
viser at den spektral oppløsningen ble forbedret med 25 % i alle spektrene. Økningen 
i SNR var varierende og i mindre grad enn forventet. Dette kan forklares med ulike 
definisjoner for volumdefinisjon på de to ulike MR systemene, noe som gav mindre 
effektiv volumstørrelse ved 3T, til tross for lik volumstørrelse.  Forskjellene var størst 
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ved kort ekkotid (TE 32), slik at det ble mindre økning i SNR ved økt 
magnetfeltstyrke, sammenlignet med lang ekkotid (TE 144). 
 
Hjernemetastaser er blitt klassifisert som egen gruppe forskjellig fra de fleste primære 
hjernetumorer. De kan stamme fra mange typer primærkreft, men pasienter med 
lunge-, bryst- eller hudkreft (malignt melanoma) er blant de som oftest utvikler 
hjernemetastaser.  Histologiske undersøkelser av vevsprøver fra metastasene viser 
ofte at de har likhet med den opprinnelige kreftsvulsten, noe som er med på å 
bestemme videre behandling av pasienten.  Dersom in vivo MRS kan gi samme 
informasjon, vil det ha betydning for raskere valg av behandling og oppfølging uten 
kirurgisk inngrep.  En hjernemetastase kan være første symptom på kreft hos en 
pasient og en klassifisering av denne kan spore opp den primære kreftsvulsten. Når 
operasjon er en del av behandlingen kan en høyoppløselig ex vivo MRS vevsanalyse 
gi utfyllende informasjon til standard histologiske analyser.  Tidligere studier med 
bruk av MRS på hjernetumorer har vist at de ulike krefttypene har særtrekk i sine 
metabolske mønster.  I artikkel III og IV er spekter av hjernemetastaser, henholdsvis 
in vivo og ex vivo blitt analysert.  Ved hjelp av prinsipalkomponentanalyse og 
regresjonsanalyse ble spektrene klassifisert i forhold til primær tumor og klinisk utfall 
fem måneder etter start av behandling.  Resultatene viser en signifikant korrelasjon 
mellom metabolske mønster og klinisk overlevelse for pasientene.  Klassifiseringen i 
forhold til type primærtumor var mindre tydelig, som kan skyldes få pasienter 
undersøkt i studiene.  En utvidet studie med et stort antall pasienter vil derfor være 
nødvendig for å få en bekreftelse på disse funnene.  Både in vivo og ex vivo MR 
spektroskopi gir metabolske bilder som kan få høy klinisk relevans. 
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Abbreviations 
BM brain metastasis (-es) 
b.w. body weight 
ca. carcinoma 
CHESS chemical shift selective sequence 
Cho choline 
CI confidence interval 
COSY correlated spectroscopy 
Cr creatine 
CSI chemical shift imaging 
FID free induction decay  
FFT fast Fourier transform.
FWHM full-width-half-maximum 
GABA γ-aminobutyric acid 
Glx glutamine and glutamate 
GPC glycerophosphocholine 
HR MAS high resolution magic angle spinning 
IDC invasive ductal carcinoma 
jMRUI java-based magnetic resonance user interface 
KPS Karnofsky performance status 
Lac lactate 
MR magnetic resonance 
MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
MRSI magnetic resonance spectroscopy imaging 
NAA N-acetyl aspartate acid 
PBS phosphate buffered saline 
PC phosphocholine 
PCs principal components 
PCA principal component analysis 
PLS partial least square 
ppm parts per million 
PRESS point resolved spectroscopy pulse 
PNN probabilistic neural network 
RPA recursive partitioning analysis 
SGA small for gestational age 
SNR signal-to-noise ratio 
SR stereotactic radiosurgery 
SVS single volume spectroscopy 
T tesla 
tCho total choline containing compounds 
TE echo time 
TR repetition time 
TSP trimetylsilyl tetradeuteropropionic acid 
VLBW very low birth weight 
VOI volume of interest 
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Summary 
 
The clinical applications of MRS have become a supplement to MR imaging (MRI) for 
diagnosis and treatment monitoring of several pathologies.  In this thesis MR 
spectroscopy (MRS) has been used to assess brain metastases in adult cancer patients 
and cerebral metabolites in frontal lobe of adolescents.   
 
Children born with very low birth weight are at risk of later neurodevelopment 
problems.  Adolescents with different birth weight were examined using MRI and MRS 
and multivariate analyses for assessing differences in cerebral metabolites.  The results 
from the multivariate analyses were consistent with observations in earlier published 
MRI findings, motor skills, psychiatric symptoms and disorders detected in the same 
participants.  The classification of the adolescents was based on metabolic pattern 
differences which were only explored by the multivariate analyses.  When the spectral 
information shows small or complex differences the interpretations become a challenge.  
In three of the four papers in this thesis, multivariate analyses were used as a tool to 
interpret the spectral information.   
 
Brain metastasis is the dominating type of brain tumors which represent an oncologic 
challenge.  The incidence of brain metastases is probably increasing due to improved 
treatment strategy of patient with primary cancer, prolonging their survival and brain 
metastases get time to develop.  In some cases patients have an unknown primary 
cancer or several primary cancers. If MRS could provide metabolic information about 
brain metastases especially in differentiating it from the primary cancer, it might be a 
supplement to the conventional diagnostics and could help to optimize the cancer 
treatment.  In the two last papers in vivo and ex vivo MRS of brain metastases were 
obtained before treatment and the spectra were analysed by using both principal 
component analysis and regression analysis.  The spectra were classified according to 
primary cancer and clinical outcome five months after start of treatment.  The results 
showed a significant correlation of spectral findings and clinical outcome of brain 
metastases patients.   
4 
Summary 
 
 
From the MR theory, signal-to-noise ratio and resolution in MR spectra should increase 
by a factor of two with double the magnetic field strength.  Different studies using in 
vivo MRS have shown that the situation varies.  In Paper II the effect of increased 
magnetic field from 1.5T to 3T was investigated in spectra obtained in patients with 
brain metastases.  The comparisons of spectral improvements in SNR and spectral 
resolution were made by ratio calculations.  The gain was smaller than expected 
probably caused by various definitions of effective volume size at different clinical 
scanners. 
 
In conclusion, in vivo and ex vivo MR spectroscopy can determine metabolic pattern on 
clinically highly relevant questions. 
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Introduction 
Brain maturation 
 
The brain and spinal cord constitute the central nervous system (CNS) which consists of 
mainly two types of cells; neurons (nerve cells) and neuroglia (glial cells).  The 
hallmark of neurons is their specialization for electrical signalling over a range of 
distances. The neuroglia maintains the environment surrounding the neurons and they 
participate indirectly in signal transmission. Three types of glial cells have been 
identified in the CNS; astrocytes with great diversity of function, oligodendrocytes 
which form myelin around nerve cell extensions (axons) and microglia the defence cells 
near blood vessels. Myelinated nerve cells constitute the white matter while un-
myelinated neurons form the grey matter in CNS (1). 
 
Brain maturation is known as a complex and lifelong process where fetal development 
and childhood are of great importance. Histological evidence has shown brain 
development as a dynamic process of progressive and regressive changes. The entry of 
neuroimaging techniques such as magnetic resonance imaging (MRI) in the middle of 
the 1980s made it possible to study brain maturation in detail. MRI enabled longitudinal 
experiments and non-invasive investigations of living subjects. This has provided more 
detailed documentation of the large-scale changes within the brain (2).  Brain 
maturation is characterized by changes in the myelination process, synaptic density and 
pathways of metabolism during the development from neonatal to adult brain. However, 
birth weight is an important factor in how successful this development will be.  Follow-
up studies of children with birth weight below 1500 g have documented increased 
prevalence of neurodevelopmental disabilities and cognitive deficits compared with 
children born at full term (3-5). Adolescents who had low birth weight have been 
studied by MRI and clinical assessment, showed correlation between cerebral 
abnormalities and psychiatric symptoms (6).  Also, MR spectroscopy (MRS) provides a 
non-invasive tool for investigation of the physiology of the CNS and its postnatal 
development. 
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Brain metabolites 
 
The chemical processes that occur when nutrients are absorbed to provide energy, build 
or repair body tissue and break down waste products to be extracted, are called 
metabolism. The chemicals involved are known as metabolites and some of them can be 
observed using MRS.  The most prominent signals in water suppressed spectra from 
healthy brain tissue is due to N-acetyl aspartate (NAA), creatine (Cr) - and choline–
containing compounds (tCho) (7-12).  NAA appears as a singlet signal at 2.0 ppm in the 
spectra and decreases in diseases such as dementia, stroke and brain tumors where 
neuronal density and/or function are disturbed (13).  The Cr signals at 3.0 ppm and 3.9 
are due to both creatine and phosphocreatine (PCr) in spectra from low field magnets 
typically used for in vivo spectroscopy (10). Cr is reported to represent the cells 
mitochondrial activity and to appear in higher concentrations in oligodendrocytes and 
astrocytes than in neurons (8,13).  In abnormalities such as brain metastases, aggressive 
brain tumors and hypoxic tissue the Cr signals decreases (8).  The signal at 3.2 ppm is 
caused by compounds which are not separable in in vivo spectra at low field.  The peak 
includes signals from free choline, phosphocholine (PC) and glycerophosphocholine 
(GPC) and is referred to as total choline (tCho) (14).  It is reported to reflect cell 
membrane synthesis and degradation and also to appear in higher concentrations in glial 
cells than neurons (8,13).  Abnormalities like brain tumors, white matter diseases and 
stroke are characterized by an elevated tCho signal while necrotic tissue show a 
decreased signal (8,15).  In pathological tissue also lactate (Lac) and lipids can be 
observed in proton spectra, often as overlapping peaks at 1.3 ppm.  A strong Lac signal 
indicates anaerobic metabolism due to impaired oxygen supply which is often seen in 
brain tumors.  Several signals represent methyl- (0.9 ppm) or methylene groups (1.2-1.4 
ppm) of lipids/fatty acids which are normally only seen in spectra from diseased brain 
tissue such as tumors, stroke and demyelinating disease (7-9,11,16,17).  Provided short 
echo time and sufficient magnetic field (> 3T) also metabolites such as glutamine and 
glutamate (Glx) at 2.2-2.4 and 3.6-3.8 ppm or glycine (Gly) at 3.56 ppm and myo-
Inositol (mI) at 3.52 can be separated and observed in spectra in vivo (10,18) (Fig. 1).   
Ex vivo spectra from intact tissue or extracts obtained using high resolution instruments, 
give further metabolic information about these and many other metabolites due to 
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increased spectral resolution as demonstrated in Paper IV and several previous papers 
(10,19-21).  
 
 
 
 
  
 
 
Figure 1.  In vivo spectrum of healthy brain tissue (white matter) obtained at 3Tesla. 
Tentatively assigned peaks based on published chemical shift. Abbreviations are 
explained in the text above (MRI, MRS and processing parameters are described 
in paper II). 
 
 
 
Brain metastases 
 
Brain metastases (BM) are the dominating type of brain tumors and are most frequently 
caused by haematogenous spread from different primary cancers such as lung (40-50%), 
breast cancer (15-17%) and melanoma (10-11%) (22,23).  BM often appear as multiple 
intracranial lesions in the cerebral hemisphere (80%), cerebellum (15%) or brain stem 
(5%) and the disease might change dramatically the patients’ quality of life due to 
neurologic, cognitive and emotional difficulties (24-26). The patients represent a 
significant oncologic and health care providing challenge. Long-term survival after 
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development of BM is rare as median survival is estimated in months (23,27). The 
incidence of BM is expected to increase due to improved systemic treatment of primary 
cancers involving a larger number of patients who lives long enough to develop 
symptomatic BM.  An increased incidence might also be a consequence of greater 
access to improved neuroimaging techniques and previously detecting small metastases 
(23,25,28,29). 
 
All kinds of primary cancers are classified in subgroups related to the type of tissue or 
cells they originate from.   The cancer cells might infiltrate into adjacent tissue and 
metastasize through the lymphatic system or hematogenous spread to distant organs, 
such as bone, liver, lung, or brain (30,31).  The metastases are classified by the 
histopathological appearance and the medical terminology relates to the cell of origin 
(32). Malignant neoplasms of epithelial cell origin are called carcinomas which may be 
further classified after the tissue or organ of origin.  Adenocarcinoma denotes a lesion in 
which the neoplastic epithelial cells grow in glandular tissue while squamous cell 
carcinoma denotes neoplasms in which the cells resemble stratified squamous 
epithelium. Metastases showing no distinct histopathological appearance are classified 
as undifferentiated carcinomas (32).   
 
Certain primary cancers have a predilection to metastasize to the brain (22,33).  
Malignant melanoma and small-cell-lung carcinoma have been reported as the most 
aggressive contributors to secondary brain tumors while the metastasizing of breast and 
non-small lung carcinomas is not as pronounced.  Patients with kidney or colon 
carcinoma are also within the risk group of developing BM, yet this is not as common 
as the cancer types mentioned above (33).   
 
Diagnosis and treatment of brain metastases 
 
Indications of elevated intracranial pressure or progressive focal neurologic signs, as 
well as an epileptic seizure in a patient with prior history of primary cancer are possible 
symptoms of brain tumors (25,26).  In some cases BM cause the first symptoms of a 
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systemic cancer (34,35).  The prognosis varies with type and grade of primary cancer, 
age and performance status at the time of diagnosis as well as extent of extracranial 
disease (28,35-37).   Hence, identification of the origin of metastases is of clinical 
interest to get optimized treatment and control the systemic primary cancer (34).  
 
In general, the use of non-invasive, neuroimaging modalities like magnetic resonance 
imaging (MRI) or computed tomography (CT) in brain tumor diagnosis is of great 
importance.  A combination of MRI and MR spectroscopy (MRS) gives more detailed 
information and makes a further differentiating or classifications of brain tumors 
possible.  However, a definite diagnosis can only be confirmed by histological analyses 
of tumor tissue samples.  The specific diagnosis sets the guidelines for treatment 
strategies (Fig. 2).  Provided surgically accessible, the treatment of single BM is most 
often surgical resection followed by radiotherapy and/or chemotherapy.  Multiple and 
non-operable single BM might be treated by using whole brain radiation therapy 
(WBRT) and/or chemotherapy.  Patients with BM and symptomatic peritumoral oedema 
are also treated with corticosteroids (33,38).  Before any decision is made on treatment 
strategy the patient’s performance status is evaluated.  Karnofsky performance status 
(KPS) is one method of classification where KPS of 50 describes a person needing 
considerable help and medical care while a KPS 100 indicate a patient with no affliction 
or subjective symptoms of the disease (39).  Three prognostic classes for patients with 
BM have been developed using recursive partitioning analysis (RPA) of a large 
database (40).  The three-class system (Fig. 3) indicating clinical status involving the 
patient’s KPS score, age, control of primary cancer, extracranial metastases and number 
of BM observed (36,40).   
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Brain metastases (BM)
Controlled Uncontrolled
Single BM
Diagnosis:
Status primary systemic cancer:
Numbers of BM:
2-3 BM
(< 3 cm) ≥ 4 BM
SR 
± WBRT
If surgically 
accessible: Surgery 
± WBRT
WBRT, 
± chemotherapy
or corticosteroids
Treatment 
options:
 
 
Figure 2.  Simplified BM treatment decision diagram, modified after Ewend et al (27).  
    SR: Stereotactic radiosurgery, WBRT: whole-brain-radiation therapy. 
 
 
 
 
 
ROOT
KPS ≥ 70 KPS < 70
PRIMARY CA. PRIMARY CA. CLASS III
CONTROLLED UNCONTROLLED
AGE < 65 YEARS AGE ≥ 65 YEARS CLASS II
METASTASES METASTASES
BRAIN ONLY BRAIN &OTHER SITES
CLASS I
 
Figure 3. Scheme for RPA classification of BM patient (class I, II or III) modified after Gaspar  
   et al. 2000 (36).  KPS: Karnofsky performance status. Ca: cancer. 
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Histopathology 
 
Histopathology is the gold standard for accurate diagnosis of tumor tissue samples.  To 
prevent tissue degradation during storage, the samples are either frozen in liquid 
nitrogen or fixed in formalin.  Microscopic sections are made and prepared for 
examinations by a pathologist. The histopathological investigations in this study include 
interpretation of tumor type and evaluation of any apoptosis, necrosis, gliosis, and 
fibrosis present.  
 
Histopathological analyses reveal presumptive source of malignant tissue due to the 
cells characteristic, as well as tumor grade.  Tissue samples of anaplastic carcinomas 
showing no distinct histological appearance are described as undifferentiated 
carcinomas.  Apoptotic tissue is a result of programmed cell death which may occur 
after un-repairable cell damage or virus infection.  The process can be induced by the 
cell itself, by the surrounding tissue or by the immune system.  Apoptotic cells show 
several morphologic characteristic that can be seen under a microscope after appropriate 
staining. Necrotic tissue is a result of a non-controlled cell death called necrosis which 
can be seen in various pathological settings, such as malignant tumors, infarction and 
infection.  Some malignant tumors induce a dense, abundant fibrous stroma, called 
desmoplasia (32,41).  A phenomenon found in most pathological reactions where 
neuronal cell loss is involved, is the formation of gliotic tissue which consist of a dense 
fibrous network of proliferated astrocytes.   
 
In vivo MRS 
 
MRI was introduced as a clinical modality in the early 1980s and is now in worldwide 
use as a clinical imaging technique.  No adverse biological effects from exposure to the 
magnetic fields or radiowaves used have been reported.   
 
Gadolinium-enhanced MRI has become the most important imaging method for 
examination of brain tumors. BM appears as ring contrast enhancing lesions most often 
located in the gray-white matter junction.  MRI combined with MRS might provide 
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evidence for cellular injury after traumatic brain injury, brain tumors not visible by 
conventional imaging techniques, and detailed characterization of lesions (16,17,42,43).  
A spectrum obtained from a chosen volume of interest (VOI) with standard gadolinium-
enhanced MR images in all three planes of orientations are presented in Fig. 4.  
 
 
 
 
 
 
 
 
 
Figure 4. (a) Coronal, (b) sagittal and (c) axial planes of gadolinium-enhanced T1-weighted MRI 
at 3T of a patient with BM from malignant melanoma, showing the VOI localized   
within one of the observed metastases. A short echo time spectra obtained in the VOI 
is presented (d). 
 
 
MRS allowing investigations of brain metabolism in vivo is of great importance where 
resection of tissue for ex vivo analyzing is undesirable or unobtainable. Examination of 
proton (1H) and phosphorous (31P) are the most important nuclei used in clinical 
systems.  However, proton spectroscopy is the preferred method due to the widespread 
distribution of proton in most compounds and because it has the sensitivity to provide 
adequate signal-to-noise ratio (SNR) from small VOI.  It is also easier to apply using 
standard MRI systems.   
 
To obtain high quality spectra some requirements must be fulfilled.  First, a well 
shimmed static field is needed, secondly water suppression must be performed (due to 
the huge amount of abounded proton) and at last localization scheme must be used (44-
46).  On standard clinical MR systems the optimization of linewidths is done using an 
autoshim procedure developed by the system vendor.  Water suppression might be 
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performed using the chemical shift selective sequence (CHESS) where presaturation 
pulses are used, or other techniques.  The localization sequence PRESS (point resolved 
spectroscopy pulse) uses spin echo sequences which provide optimal signal-to-noise-
ratios.   
 
In vivo spectra might be obtained from single VOI or by multi-voxel spectroscopy 
(MRSI) from single or multi slices using long or short echo times (TE).  Metabolites 
relaxation time (T2) decides whether they are spectroscopic visible or not. Large 
molecules such as lipids move slowly and their T2-values are short, hence these 
metabolites are observed only in short echo time spectra.  Also the repetition time (TR) 
is important, since short TR might cause saturations and bad spectrum quality.  Single 
volume MRS is particularly suited for studying lesions like brain tumors due to the 
short acquisition time needed.  When an overall view of brain metabolism or 
investigations of brain tumors heterogeneities are needed MRSI will provide spectral 
data with spatial information (47).   
 
The clinical applications of in vivo 1H MRS have involved examination of a variety of 
diseases or abnormalities, from pediatric brain maturations differences to breast or 
prostate cancer and neurological disorders (11,48-50).   MRS can classify brain tumors 
into different subgroups such as glioblastomas, astrocytomas and BM  (7,51,52). 
Studies of cancer treatments effect have been performed using both single volume MRS 
and MRSI. Observed changes in metabolite ratios were interpreted as treatment effect 
(53,54).  Appropriate analysis and interpretations of MR spectroscopic data have been 
proposed in previous work as additional tool together with more traditional clinical 
findings for predicting survival of patients with gliomas (55,56). 
(c) 
 
High resolution magic angle spinning (HR MAS) 
 
High resolution magic angle spinning (HR MAS) is an ex vivo MRS technique which 
has become important for analyzing metabolic information from intact tissue specimens 
of different origins (57-62).  Several metabolites have been identified and an example of 
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a typical HR MAS spectrum some is given in Fig. 5. Comparisons of HR MAS and 
conventional MR spectra of perchloric acid extract have reported similar results (20,62).  
The clue of the MAS method is the tilting of the solid sample by an angle of 54.7º to the 
direction of the static magnetic field and by spinning the sample at great speed about its 
own axis, the line broadening of signals is reduced due to a reduction of the anisotropic 
interactions in the tissue (63-65).  Large molecules such as lipids have short T2-
relaxation time and might still appear as broad signals.  These signals can be reduced in 
spin echo sequences, resulting in even better resolved spectra (66).   
 
 
 
 
Figure 5. HR MAS spin echo spectrum (TE 32 ms) from brain metastasis of lung carcinoma,  
  showing a selection of identified metabolites.  In frame:  Schematic presentation  
   of magic angle spinning (MAS) principle (with permission from B. Sitter).  
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Assignments of spectra from biological samples are based on comparisons of peaks 
multiplicity and chemical shift with previously reported values (10,20,62). A one-
dimensional (1D) spectrum as shown in Fig. 5 might be too complex for complete 
interpretation due to numerous metabolites.  However, using an additional spectral 
dimension more detailed information becomes available.  Two-dimensional (2D) 
homonuclear correlated spectroscopy (COSY) gives information originated from 
neighbour nuclei’s interactions and their chemical shifts are extracted (Fig.6).   
 
Examination of intact tumor tissues using HR MAS analysis has been suggested as a 
supplement to histopathology and a contribution to improve brain tumor diagnosis 
(57,58,67). The similarities between ex vivo and in vivo spectra found in studies of 
different primary brain tumors allow a better interpretation of in vivo MR spectra 
(20,61,68-70). Recent studies have shown that HR MAS metabolic phenotypes correlate 
to clinical parameters both in breast and prostate carcinoma (67,71). 
 
 
 
Figure 6. HR MAS 2D correlated spectroscopy obtained in intact tissue sample of BM from 
  breast carcinoma.  The numbers indicate chemical shifts for the observed cross peaks 
  between neighbouring molecules. 
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Multivariate analyses 
 
Multivariate analyses constitute an important statistical help to interpret complex data 
sets such as spectroscopic data (72).  The use of multivariate analyses are mainly based 
on three groups of purposes; exploration, classification and prediction of spectral data.  
Both supervised and unsupervised methods are established.  Unsupervised methods 
group the samples on basis of input variables only and are typically used for exploration 
and classification.  Principal component analysis (PCA) is such a method, while 
principal least square (PLS) regression and probabilistic neural network (PNN) are 
examples of supervised methods.  These methods utilize prior knowledge about pattern, 
groups or other measured variables directly in order to provide predictions, e.g. of 
outcome.  Establishment of an adequate model, based on representative samples, makes 
a prediction of values from unknown samples possible. 
 
PCA, compresses or simplifies high-dimensional data by finding a linear combination 
of the original variables so the variance is maximized and new uncorrelated variables, 
principal components (PC) are created. The resulting score plots and loading profiles 
visualize the differences and correlation between the samples.  The score plot of PC1 
and PC2, or PC3 gives the main information content in the data set.  The correlations 
between the variables and PCs are called the PCs loadings.   The loading profile for 
each PC give the importance of each variable or metabolite for the variation described.   
 
PLS regression finds correlations between two data sets simultaneously, by using one 
set of variables to predict another. The spectral data are reduced into PCs which explain 
most of the variation in both predictors (MR spectra) and responses (e.g. clinical 
parameters).  The regression coefficients summarize the relationship between all 
predictors and the given response(s). Classification based on differences between 
several classes with PLS is called PLS-discriminant analysis (PLS-DA). For both PCA 
and PLS the explained variance is measured as a percentage of the total variance in the 
data.  It is the proportion of variation in the data accounted for by the current PC.  The 
total residual and explained variance indicates how well the model fits the data set.  An 
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optimal model shows explained variance close to 100 % and residual variance close to 
zero with few components (PC’s) (72).   
 
PNN is a type of radial basis network suitable for classification problems. PNN 
networks are organized in three layers: input, pattern and summation. The input layer 
has as many elements as there are individual parameters (selected chemical shift region) 
needed to describe the samples to be classified. The pattern layer organizes the training 
set such that an individual processing element (neuron) represents each input vector. 
The summation layer has as many processing elements as there are classes to be 
recognized and simply collects the outputs from all hidden neurons of each respective 
class. The products of the summation layer are forwarded to the output (one neuron for 
each data class), where the estimated probability of the new pattern being a member of 
that data class is computed. The stopping criterion involves minimizing the average 
percentage of incorrect classifications over all categories.   
 
Validation of a model is important for evaluation of its modelling ability.  An estimation 
of expected error when fitting new, similar data to the model is then made.  Use of a 
separate test set is the optimum choice, but in practice not always obtainable. One of the 
major considerations in model development is that the training set must contain the 
extremes of the behaviour of the patterns associated with each class since the methods 
do not extrapolate. Thus, randomly selection of samples for external validation has 
limitations that can be mitigated by ensuring that the training data set is optimized with 
respect to this requirement. This can be done by using an algorithm such as the Kennard 
Stones, for splitting data sets into two subsets; calibration and test sets (73).  Both 
subsets of samples have to be representative for the original data set to avoid high 
prediction error and a bias. Another option in validation is to simulate a test set by using 
full cross validation (leave-one-out), where the same samples for both estimation 
(calibration) and testing (validation) the model are used.  During this process of 
modelling one sample is kept out while the calibration is performed on the rest of the 
samples.  Values are then predicted for the left-out sample and prediction residuals are 
calculated. The process is repeated until all samples have been kept out once.  Finally 
all prediction residuals are combined to find the overall root mean square error of 
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prediction (RMSEP).  The number of PCs to retain in the model should be determined 
by the PC where RMSEP and residual variance are minimized (72). 
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Aims of present work 
 
The main objective of this thesis was to investigate the feasibilities of proton MRS in 
four different studies as follow: 
                                                                                                                                                                   
 
1. Implement multivariate analyses for assessing differences in cerebral 
metabolites in adolescents with low birth weight assessed by in vivo MRS at a 
1.5T clinical system.  
 
2. Address the effect of increased magnetic field from 1.5T to 3T, regarding signal-
to-noise ratio and spectral resolution in spectra obtained in patients with brain 
metastases. 
 
3. Investigate the benefits of in vivo MRS in characterization of brain metastases 
and correlation to clinical outcome. 
 
4. Assess metabolite profiles of brain metastases using ex vivo HR MAS MRS and 
relate the spectral data to clinical outcome for the patients. 
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Materials and methods 
 
A summary of the different MR systems and data analyses used in the four presented 
papers is given in Fig. 7.  
 
 
Paper I Paper II Paper III Paper IV
14.1T3T1.5T
PCA, 
PLS
PCA, 
PLS
PNN, 
PLS
SNR, 
Resolution 
comparisons
 
  
Figure 7. Schematic presentation of the MR-systems with different magnetic field strength and  
   data analyses used in this work: PNN: probabilistic neural network, PLS: partial least 
  square regression, PCA: principal component analysis and SNR: signal-to-noise ratio  
   used in the different papers (I-IV). 
 
Patients and healthy volunteers 
 
The subjects in Paper I were enrolled during the period of year 2000-2003 in a follow-
up study of 14-years old adolescents with different birth weights, including in vivo 
MRS as one of several examinations  (74-77).  During 1.5 years the patients for studies 
II-IV were recruited among cancer patients at St.Olavs Hospital in Trondheim with 
diagnosis BM.  The inclusion criteria were the diagnosis and patient’s age (> 18 year).   
 
All projects in this thesis were approved by the Regional Committee for Medical 
Research Ethics.  The enrolled patients and healthy volunteers gave written informed 
21 
Materials and methods 
 
 
consent to participate. For the study in Paper I, both the adolescents and their parents 
signed the informed consent. 
 
Tissue samples 
 
Tissue samples from different BM examined by HR MAS MRS are presented in paper 
IV.  The tissue samples obtained from patients undergoing scheduled surgical resection 
were stored in liquid nitrogen immediately after dissection. In order to prevent 
biochemical and structural degradation the specimens were kept at this temperature until 
further analyses were made.  In order to maintain the tissue frozen as much as possible 
the preparation were performed mostly on ice. The samples were sliced to fit the MAS 
rotor (4 mm o.d., 50 µl) filled with PBS-buffer (40 µl, a mixture of trimetylsilyl 
tetradeuteropropionic acid (TSP, 1mM), sodium formate (CHNaO2, 1mM), and 
phosphate buffered saline (PBS) in deuterium water (D20)).  Excess PBS-buffer was 
removed when assembling the rotor.  The mean ± SD sample weight was 10.0 ± 4.0 mg. 
 
Histopathology  
 
Routine histopathological were performed of tumor tissue from all patients. During 
surgery one part was sent for this analysis, while another part was analyzed after the HR 
MAS examinations.  The histopathological information used in this work where the 
diagnosis from the routine histopathology and tissue composition of the HR MAS 
sample, such as the fraction of tumor, necrosis or other types of tissue.  
 
In vivo MRS 
 
Clinical MR systems with standard clinical head coils at both 1.5T (Siemens Magnetom 
Symphony, Erlangen, Germany) and 3T (Philips Intera, Best, The Netherlands) were 
used in Paper I, II and III.  The examinations of patients and healthy volunteers were 
performed by radiographs.  Patients were examined using intravenous contrast injection 
of 0.1 mg/kg b.w. Gadodiamide (OmniscanTM, GE Healthcare).   
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The MRI protocol consisted of conventional T1 - and T2 - weighted images in all three 
directions (transversal, sagittal and coronal plane) before single voxel 1H MRS was 
performed on a localized VOI.  MRS was performed using the point resolved 
spectroscopy pulse sequence, PRESS, with 2000 ms in repetition times (TR) and 
different echo times (TE 30/32/135/144 ms).   If necessary the volume was slightly 
rotated to optimize the VOI selection and reduce possible partial volume effects.  
Phantom measurements in Paper II were performed as quality checks of the 
examinations using the same sequences.  The phantom consisted of an agar-mixture 
containing N-acetyl aspartate acid (NAA), choline (Cho), creatine (Cr) and lactate (Lac) 
which are compounds known as brain metabolites observed in spectra of healthy brain 
tissue (78-80).  
 
The spectra were processed using the program “java magnetic resonance user interface”, 
jMRUI (81,82). The FID was zero-filled to doubled number of points and a Lorentzian 
filter of 2Hz was applied before Fast Fourier Transformation (FFT). To suppress the 
residue peak of the water signal, Hankel Lanczos Singular Values Decomposition Filter 
(HLSVD) was used. Chemical shift referencing was set relative to the tCho signal at 3.2 
ppm.  Finally, the algorithm AMARES was applied to estimate the linewidth of each 
metabolite peak in the spectra (81,82).  
 
HR MAS MRS 
 
The HR MAS spectra were obtained using a Bruker Avance DRX600 spectrometer 
equipped with a 1H/13C HR MAS probe with magnetic field gradients aligned with the 
magic angle axis. The spin rate for all experiments was 5 kHz and the temperature 
within the probe was fixed at 4°C.  A single pulse experiment (zgpr; Bruker) and spin 
echo experiments (cpmgpr; Bruker) using effective echo times of 32 and 285 ms were 
performed with water presaturation (83).  All spectra from these one-dimensional 
experiments were obtained within 1 h and 30 minute. Immediately after the HR MAS 
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analysis the tissue specimens were fixed in formalin for subsequent histopathological 
examinations. 
 
Two-dimensional homonuclear correlated spectroscopy (COSY) were performed to 
assist the spectral assignment of the one-dimensional spectra.  The COSY spectra were 
zero-filled and multiplied with a sine window function in both dimension before Fourier 
transformation.  Also previous reported HR MAS spectra were used  to assist the 
spectral assignment (20,62,84,85). 
 
The HR MAS spectra were processed using the program WIN-NMR (Bruker). Before 
Fourier transformation the FID was multiplied with a 0.3 Hz exponential line 
broadening.  Chemical shift referencing was performed relative to the TSP signal at 0 
ppm. 
 
Multivariate analyses 
 
Different methods of multivariate analyses were used in this work (Fig. 7).  All spectra 
were checked and approved regarding technical quality criteria (FWHM of the water 
peak signal) before they were converted to ASCII-files and transferred to the software 
program Unscrambler (CAMO, Norway) (Paper III and IV) or Neuroshell Classifier 
(Ward System Groups)(Paper I).  The chemical shift range of interest was selected and 
the spectra were either peak aligned with an algorithm (Paper I) or calibrated (Paper III 
and IV) to adjust for small chemical shift differences. Peak alignment was considered 
unnecessary for the spectra in Paper III and IV, since the PCA and PLS results showed 
no chemical shift variations within the three and four first PCs, respectively.  Finally, 
baseline offset was corrected and the spectra mean normalized in order to eliminate the 
differences in sample weight (ex vivo spectra) or volume size (in vivo spectra) before 
the multivariate analyses were performed.  
 
PCA was applied in order to identify clustering of spectra due to origin of metastases 
based on examination of score plots and loading profiles (Paper III and IV). The 
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chemical shift regions selected in these studies were the resonances from 3.4 - 0.7 ppm 
and 4.7 – 0.7 ppm, respectively.  On the same spectral data PLS was applied in order to 
relate clinical outcome of the patients (survival or not at five months after first MR 
examination) to the spectral data (obtained at first MR examination) (Paper III and IV).   
 
Both PNN and PLS-DA were used to compare in vivo 1H spectra obtained from white 
matter in frontal lobe of adolescents with low birth weight and controls (Paper I). Only 
the chemical shift region containing the resonances from NAA (2.0 ppm), Cr (3.0 ppm) 
and tCho (3.2 ppm) were selected for these analyses.  
 
General statistical analyses 
 
Non-parametric tests were also applied to evaluate spectral differences. The Kruskal-
Wallis test was used to compare means of metabolite ratios in Paper I, while Mann-
Whitney U test was used to compare SNR and resolution differences between the 
spectra obtained at different magnetic field strength in Paper II.  The significance of the 
estimated correlation factors between measured and predicted y-variables in both Paper 
III and IV was ascertained by using the Pearson correlation test (two-tailed).  
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Paper I  
 
Bathen T.F., Sjøbakk T.E., Brubakk A.M.,  Skranes J., Vik T., Martinussen M.,  
Myhr G., Gribbestad I.S., Axelson D.E. Pediatric Radiology (2006) 36: 802-809. 
 
CEREBRAL METABOLITE DIFFERENCES IN ADOLESCENTS WITH LOW BIRTH WEIGHT.  
ASSESSMENT WITH IN VIVO PROTON MR SPECTROSCOPY. 
 
Children with very low birth weight (VLBW; birth weight ≤ 1500 g) are especially at 
risk of later neurodevelopment problems, while infants born at term but small for 
gestational (SGA; birth weight < 10th percentile) are at some risk of evolving 
neurological impairments.  The objective of this study was to evaluate possible 
differences in brain metabolites among VLBW and SGA children compared with a 
control group; children born at term with birth weight > 10th percentile, using in vivo 
MRS at 1.5T and univariate and multivariate analysis. Spectra (n=54) were acquired 
from volumes localized in the left frontal lobe, containing mainly white matter. Peak 
areas of NAA, tCho and Cr were estimated and peak ratios determined.  The calculated 
metabolite ratios NAA/Cr, tCho/Cr and NAA/tCho showed no significant differences 
between the groups when using the Kruskal Wallis test.  By application of PNN a 
correct classification of 52 of the 54 adolescents with sensitivity and specificity 
exceeding 93% for all groups were achieved. Small, yet systematic, differences in 
metabolite distribution among the groups were thus confirmed. 
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Paper II 
 
Sjøbakk T.E., Lundgren S., Kristoffersen A., Singstad T., Svarliaunet A.J.,  
Sonnewald U. Gribbestad I.S. Acta Radiologica (2006) 45 (5):501-508. 
 
CLINICAL 1H MR SPECTROSCOPY OF BRAIN METASTASES AT 1.5T AND 3T 
 
Previous studies of the effects of increased magnetic field have found variable 
improvements in signal-to-noise-ratio and spectral resolution in spectra when similar 
anatomic regions and analyzing parameters are compared.  The aim of this study was to 
investigate whether improvements in SNR and spectral resolution were found in spectra 
from patients with BM obtained at higher magnetic field strengths using standard 
clinical instrumentation. Six patients with BM, thirteen healthy volunteers and a 
phantom containing brain metabolites were examined using two clinical MR 
instruments operating at 1.5T (Siemens) and 3T (Philips) with standard clinical head 
coils. The spectra were obtained using the PRESS pulse sequence, echo times 32 ms 
and 144 ms and repetition time 2000 ms from a volume-of-interest (VOI) with size 
15x15x15mm3.  SNR and spectral resolution of the metabolites NAA, tCho and Cr were 
compared at 1.5T and 3T.  In general spectral resolution was improved by 25-30 % at 
higher magnetic field strength. Only minor improvements in SNR were obtained at 3T 
using short echo time and 20-50% at long echo time. Several factors influence the SNR 
of MR spectra, such as definition of the actual VOI size, which can vary between 
different MR systems. The effective VOI sizes have great impact on the measured SNR. 
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Paper III 
 
Sjøbakk T.E., Johansen R., Bathen T.F., Sonnewald U., Kvistad K.A., Lundgren S., 
Gribbestad I.S. Submitted BMC Cancer, 2007. 
 
METABOLIC PROFILING OF HUMAN BRAIN METASTASES USING IN VIVO PROTON MR 
SPECTROSCOPY AT 3T. 
 
Brain metastases are an oncologic challenge with general poor prognosis. Proton (1H) in 
vivo MRS can be used to quantify metabolites and monitor response to therapy in brain 
tumors, thereby allowing non-invasive monitoring of tumor biochemistry. The 
objectives of this study were to investigate the feasibility of using proton MRS and 
multivariate analyses to characterize BM originating from different primary cancers, to 
assess changes in spectra during radiation treatment and to correlate the spectra to 
clinical outcome for the patients after treatment.  Single volume 1H MRS was 
performed on patients (n=26) with BM using a 3.0T clinical MR system. The spectra 
were obtained before start, immediately after and two months after end of treatment.  
Signals from lipids and choline containing compounds dominated the MR spectra.  The 
spectral data were analyzed by using principal component analysis (PCA) and partial 
least square regression analysis (PLS) in order to identify any differences in the 
metabolic pattern due to origin of metastases and to relate clinical outcome (survival) of 
the patients to spectral data from the first MR examination. The PCA results indicated 
that BM from primary lung and breast carcinoma were separated into two clusters, 
while the metastases from malignant melanomas showed no uniformity. The PLS 
analysis showed a significant correlation between MR spectral data before start of 
treatment and survival five months after MRS. 
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Paper IV 
 
Sjøbakk T.E., Johansen R., Sonnewald U., Juul R., Torp S., Lundgren S., Gribbestad 
I.S. Accepted by NMR in Biomedicine, 2007, in press. 
 
CHARACTERIZATION OF BRAIN METASTASES USING HR MAS MR SPECTROSCOPY.  
 
The overall prognosis for patients with BM is generally poor.  Survival varies with type 
of primary cancer, age and performance status at the time of BM diagnosis as well as 
extent of extracranial disease.  The objectives of this study were to explore spectral 
characteristics of BM with focus on origins of the primary cancer, and to evaluate the 
correlation with clinical outcome for the patients using multivariate analyses. HR MAS 
MR spectra (n=26) were obtained from patients (n=16) with BM using a Bruker Avance 
DRX600.  Standard pulse-acquired 1H and spin echo (TE 32 and 285 ms) spectra were 
obtained. The data was examined using PCA and PLS regression relating spectral data 
to clinical outcome. The PCA score plot of pulse-acquired HR MAS spectra showed a 
trend of clustering due to different origin of the metastases, mainly based on differences 
in the lipid signals at 1.3 and 0.9 ppm.  The short echo time spectra gave the best PLS 
results.  Spectra of patients who passed away before five months after surgery appeared 
to cluster in the lower left quadrant of the score plot. Due to the possibility of 
differentiating metastases related to origin and predicting survival by PCA and PLS 
analysis, these type of analyses have a great potential to be useful tools in diagnosis of 
cancer patients in the future. 
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Characterization of brain metabolites in adolescents 
 
The ability to noninvasively obtain biochemical information by using in vivo MRS has 
been utilized in several studies of the pediatric brain.  These studies have revealed MRS 
as useful in characterization of brain maturation and malignancy of pediatric brain 
tumors, as well as assessing treatment response (42,86-88). MRS might also provide 
information relevant to understand disease processes in pediatric brain, such as 
genetically directed structural and metabolic diseases without surgery (48).   Children 
with low birth weight have been found to be at some risk of evolving neurological 
impairments (3,4,89).   In the purpose to evaluate cerebral metabolite differences in 
adolescent born with very low or normal birth weights, single volume MRS were 
performed in their frontal lobe where no MRI pathologies were observed (Paper I).  The 
spectral differences between the groups were too small to be resolved by standard 
analyses such as peak ratios and univariate statistical test.  This might be due to the 
uncertainties in the peak integrals estimation from in vivo spectra which might be 
inaccurate due to distorted base line and overlapping peaks such as tCho.  As 
demonstrated in previous studies neural networks are able to resolve hidden spectral 
differences (90-92) and the use of PNN a classification of the three groups was achieved 
based on small, yet systematic variations in the metabolic distribution in the 
adolescents.  This was consistent with clinical observations of motor skills, psychiatric 
symptoms and disorders diagnosed in the same participants in other studies (3,4).   
 
Characterization of brain metastases 
 
Biochemical monitoring of cerebral neoplasms using MRS has during the last two 
decades provided useful information about classification, type and grade of especially 
primary brain tumors (7,47,93). Also a decision support system for diagnosis and 
grading of brain tumors using in vivo MRS has been developed (52).  In general BM are 
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classified as one subgroup of brain tumors (52,94).   However, the spectral data from 
the different BM described in Paper III and IV indicated that subgroups of BM exist.  
The PCA analysis of short echo time in vivo spectra indicated separation of metastases 
originating from breast and lung carcinoma in different clusters while the metastases 
from malignant melanomas showed no uniformity.  In Paper IV only two patients with 
metastases of breast carcinomas were included and comparison to the previous study 
was not rational.  However, the metastases from colorectal carcinomas were clearly 
separated from lung carcinomas and malignant melanoma metastases in the score plot 
(Paper IV).  The differentiation was not based on single metabolites but rather on 
multiple differences in the metabolic patterns.  Multivariate analyses were necessary to 
resolve these small, but systematic differences. 
 
In vivo MRS 
 
Use of higher magnetic field strength (≥ 3T) is now common in both research and 
clinical settings.  With the increased access to 3T human MR scanners, comparisons of 
high field brain spectroscopy to standard clinical system are relevant.  Theoretically, an 
increment by two in field strength should double the SNR and increase the spectral 
resolution (95-98)  However, in addition to magnetic field strength, SNR depends upon 
the acquisitions parameters, RF coil sensitivity, T1 and T2 relaxation times and 
shimming.  Studies comparing spectra from 1.5T and 3T/4T systems have indicated that 
only half of the theoretical increase in SNR and improvement in spectral resolution of 
20 – 50% were obtained when similar anatomic regions and parameters were used (95-
97,99). Our study (Paper II) of BM examined at both 1.5T and 3T systems demonstrated 
the same.  The acquisition parameters were chosen as equal as possible at the two 
different MR systems. The VOI size for a selected metastasis was the same at both 
systems and the same radiographer performed both examinations. The position of the 
VOI was attempted to be equal.  However, the phantom measurements showed no 
spectral improvement in SNR at short echo time and close to a two-fold increase at long 
echo time, indicating differences depending on the chosen acquisition parameters.  The 
definitions of the fixed VOI sizes at the two MR systems gave different effective size of 
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VOIs, which is crucial for the SNR (Paper II).  This effect was largest at short echo 
time. The T2 relaxation times for each metabolite have been reported to decrease to 
various degrees with increased magnetic field (100,101).  By correcting the SNR for the 
T2 effect of each metabolite observed in Paper II, equal SNR for the two echo time 
measurements at 1.5T for healthy volunteers and phantom were obtained, while at 3T 
the values at long echo time become nearly double the corresponding SNR value at 
short echo time.  The difference in effective volume size caused by the definition of 
pulse bandwidths might be the explanation.   
 
The improvement in spectral resolution with increased magnetic field has in previous 
work been demonstrated by qualitatively comparisons (95-97).  In Paper II we 
established the equation given in Fig. 8 to estimate the separation of the tCho and Cr 
peaks. The difference in resolution between the MR systems was thereafter given in 
percentage in the paper.  A limitation of high field scanning is the increased 
susceptibility artifact caused by magnetic field inhomogeneities (102-104).  In 
heterogeneous tissue like BM this might disturb both spectral resolution and SNR.   
 
)2/b2/a(cx +−=
 
Figure 8.  Equation used for estimation of differences in resolution between spectra obtained at 
different magnetic field. X: resolution, c: distance between peaks, a and b: ½ Full-width-half-
maximum of Cho and Cr peak, respectively. All variables are given in ppm. 
 
MRS is an image-guided technique where the image quality of the anatomy and 
pathology of interest is of great importance for the selection of VOI localization.  Of 
several localization sequences the pulse sequences PRESS and STEAM (stimulated 
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echo acquisition mode spectroscopy) are most common.  STEAM is often used at short 
echo time when TE < 30 ms is required, while PRESS which provides better SNR is 
preferred when longer TE can be used.  All spectra in this thesis were obtained using 
PRESS with different echo times, since STEAM was not implemented at 3T at the time.  
To obtain optimal quality of biochemical information from in vivo MR spectra it is also 
important to avoid motion artifact.  Patient’s movement might result in contribution 
from outside the chosen anatomical VOI.  Care was taken to avoid this kind of artefact 
as much as possible. 
 
HR MAS MRS  
 
The HR MAS technique gives high quality MR spectra of whole tissue samples with no 
special pre-treatment (61,62,105).  The storage of intact tissue and immediate analysis 
leads to minimal manipulation of the specimens. The effect of long time storage on 
biopsies biochemical profile has been discussed in previous studies (83,106).  The effect 
of high spinning rate on the sample quality following histopathologic analysis has been 
shown to be of negligible importance (70,83,107).   The HR MAS study of BM (Paper 
IV) confirm the potential of the technique demonstrated in previous studies where tissue 
samples of breast, prostate, cervix and primary brain tumors have been investigated 
(20,58,60,62,67,69).  The use of both standard pulse-acquired and spin echo sequences 
gives information about both metabolites with short and long T2 and complete the 
assignment of metabolic profiles. HR MAS spectra are also an important contributor for 
assigning in vivo spectra obtained in corresponding tissues, since they contain all 
resonances that can be observed in these (20,69).    
 
Multivariate data analyses  
 
In general, MRS differentiation of cancer tissue from normal brain tissue is often clear 
due to abnormal proportions of metabolite signals from choline containing compounds, 
NAA, Cr and lipids (7,18,47).  Peak fitting analysis and ratio calculations have been 
reported as methods to distinguish between normal and abnormal brain tissue conditions 
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(108).  When investigating spectra from same type of tissue (e.g. different BM), 
multivariate data analyses have demonstrated to be a useful tool to explore hidden 
spectral information (60,71,109-111).  The capability of multivariate data analyses to 
use the entire spectrum with all its resonances simultaneously is one of the major 
advantages.  No peak assignment is required, and overlapping resonances do not have to 
be separated in advance.  The comparison of data analyses in Paper I shows how the 
multivariate analysis PNN is able to classify different groups while traditionally 
univariate analyses (Kruskal Wallis test) did not.  Another advantage is the possibility 
to compare spectra obtained from samples with different sample weight or VOI by 
normalizing the spectra mutually before the analyses.  This was utilized both in Paper 
III and IV where two sizes of VOI and a mixture of sample weights were used.   
 
Which multivariate analysis to use, depends on the original data set and the 
investigation purposes.  PCA and PLS are well established, simple methods to be used 
if linear combination of original variables gives an adequate model, while supervised 
non-linear method such as PNN might be useful in non-linear situations. 
 
Correlation of ex vivo and in vivo MRS to clinical outcome  
 
Implementing in vivo MRS, especially MRSI has been reported to be valuable for 
treatment planning and follow-up examinations of gliomas (112).  Appropriate analysis 
of proton MRSI data is also suggested to predict survival in patients with supratentorial 
gliomas in comparison to clinical-pathological features that include invasively acquired 
data (56).  When the treatment strategy is surgery, HR MAS analysis gives easily the 
metabolic profile of the tissue which might be useful in the further diagnostic of the 
disease (71).  
 
Both Papers III (in vivo) and IV (ex vivo) present PLS results indicating a significant 
correlation between spectral data obtained before start of treatment and outcome five 
months later. The PLS results for both studies are presented in Fig. 9 as score plos of 
PC1 versus PC2 with corresponding regression coefficients.  The spectra of patients 
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who passed away before five months are clustered in the lower left quadrant of both 
PLS score plots.  The HR MAS spectra with short echo time gave the best PLS results 
regarding numbers of valid PC’s and the significance of correlation coefficients (Paper 
IV).   
 
These PLS results indicate that multivariate analysis of the MR spectra of BM before 
start of treatment can be used to predict survival in these patients on the basis of 
biochemical data of their tumors obtained by MR spectroscopy.  This provides useful 
information for individualized patient prognosis which might be used in treatment 
planning of BM patients and also for deciding termination of further therapies.  
However, the relatively small number of subjects analyzed in these studies necessitates 
further validation in larger cohorts of patients before any clinical implementation. 
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Figure 9.  PLS score plots showing the dispersion of A) in vivo MR spectra (n=27) and B)  
ex vivo HR MAS spin echo spectra (n=15) from patients who lived longer than five 
months after the first MR examination, marked as О, and those who passed away 
before 5 months, marked as †.  The two first principal components are shown with the 
corresponding regression coefficients; PC1 and PC2. The numbers represent 
following metabolites: 1: lipid (0.9 ppm), 2: lipid (1.3 ppm), 3: lactate (1.3 ppm), 4: 
lipid (2 ppm), 5: lipid (2.8 ppm), 6: creatine (3.0 ppm), 7: choline containing 
compounds (3.2 ppm), 8: taurine (3.4 ppm), 9: glycine (3.6 ppm), 10: creatine (3.9 
ppm), 11: lactate (4.1 ppm), 12: acetate (1.9 ppm). 
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Conclusion 
 
The work presented in this thesis demonstrates that the effect of doubling the magnetic 
field in BM spectra was much less than expected.  This was mainly due to differences in 
effective size of VOI, caused by different instrumental set-up for VOI definition at the 
various clinical scanners.  The improvement in spectral resolution was about 25 -30 % 
in the spectra from both BM and healthy brain tissue. 
 
Proton in vivo spectra of brain tissue giving metabolic pattern with non-significant 
differences in metabolite ratios can be resolved and classified by non-linear multivariate 
analysis (PNN).   Hence, it was possible to resolve differences in cerebral metabolite 
patterns in adolescents regarding whether they were low-birth-weight children or 
controls. These results were consistent with MRI findings, motor skills, psychiatric 
symptoms and disorders detected in the same participants. 
 
Both in vivo and ex vivo proton spectra of different brain metastases analyzed by linear 
multivariate analyses show a possible differentiation related to origin.  The present 
findings suggest that multivariate analysis of the different MR spectra can be used to 
predict survival in patient with BM on the basis of their tumors biochemical data 
obtained by MR spectroscopy.  Hence, this provides useful information for 
individualized patient prognosis which might be used in diagnosis and treatment 
planning of BM and also for decisions of termination of further therapies.  However, it 
is important that classification and prediction of survival of BM patients based on 
spectroscopic analyses is validated in larger cohorts of patients. 
 
In conclusion, in vivo and ex vivo MR spectroscopy can determine metabolic pattern on 
clinically highly relevant questions. 
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